PZ Cormay (CRM.WA) Azione Prezzo

PZ Cormay SA manufactures diagnostic reagents and laboratory equipment, offering products like biochemical rapid tests, vacuette tubes, and devices including ACCENT-300, ACCENT-200, PRESTIGE 24i, LIVIA analyzers, MYTHIC 18 hematology analyzers, and IChem 100 urinalysis apparatus. The company serves clinical chemistry, hematology, electrophoresis, parasitology, cytology, coagulation, and specific protein recognition segments. Its products are distributed through Orphee SA, which acquired 100% stake in TT Management Sp z o o on September 1, 2014, to transfer Cormay group's production and distribution activities. Orphee SA, now holding full control of Cormay's operations, manages the distribution of PZ Cormay SA's diagnostic reagents and laboratory equipment. The firm's revenue comes from selling biochemical analyzers, hematology analyzers, and related products to healthcare facilities and laboratories. PZ Cormay SA's product portfolio includes drugs, biochemical rapid tests, and devices such as vacuette tubes, targeting clinical and diagnostic markets with a focus on specialized equipment for medical analysis. The company's revenue streams are derived from the sale of its analytical devices and reagents, with Orphee SA handling the distribution after the 2014 restructuring. PZ Cormay SA's products are used in clinical chemistry, hematology, and other diagnostic segments, with specific equipment like the ACCENT-300 and MYTHIC 18 being key offerings. The restructuring plan transferred production and distribution to Orphee SA, enabling streamlined operations and market access.